



Company Profile

RedHill Biopharma, established in 2009, is a publicly traded (NASDAQ / TASE: RDHL) specialty biopharmaceutical company, headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer.

RedHill's pipeline currently includes drugs in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill's drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.


RedHill's products are based on several technology platforms and address several disease targets, thus providing for risk diversification.

RedHill's experienced management team, board of directors and advisory board, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.

Stock Performance


NASDAQ: RDHL.US ¹

Last Trade:	9.10
Trade Time:	10:33 AM ET Oct 23, 2017
Change:	-0.15 ↓ (1.622%)
Volume	28,633



TASE: RDHL ¹

Last Trade:	317.70
Trade Time:	4:24 PM IT Oct 23, 2017
Change:	-2.80 ↓ (0.874%)
Volume	182,496



Press Releases [\[View all \]](#)

Oct 23, 2017
[RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering RHB-104](#)

Oct 20, 2017
[RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer](#)

Oct 19, 2017
[RedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference](#)

Events [\[View all \]](#)

Nov 6–8, 2017
[Bio-Europe 2017](#)

Nov 27–29, 2017
[German Equity Forum](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Feb 23, 2017
[Annual Report for Foreign Private Issuers \(20-F\)](#)

RedHill Biopharma Ltd

Investor Relations Department
21 Haarbba St
Tel Aviv 64739
Israel

[Visit IR website](#)

[Sign-up for email alerts](#)

